基于PROTAC的合成杀伤性策略内源地激活系统性STING,以提高抗瘤免疫力
Ye Liu1, Maolin Jiang1, Mengchao Ding1
1School of Biomedical Sciences and Engineering, Guangzhou International Campus, South China University of Technology, Guangzhou 511442, P.R. China.
用PROTACs准DNA修复会降解PARP1和BRD4,从而诱导合成致命性. 这种方法增强了STING通路的激活,以获得由NK和T细胞介导的强有力的抗瘤免疫力.
科学领域:
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
- 分子生物学分子生物学
背景情况:
- 干扰素基因刺激器 (STING) 途径对抗瘤免疫至关重要,由细胞质DNA激活.
- DNA 修复机制通过防止细胞质 DNA 积累来限制 STING 激活.
- 针对DNA修复途径提供了一种潜在的策略,以增强STING介导的免疫力.
研究的目的:
- 开发一种新的治疗策略,使用化向仿真体 (PROTACs) 来降解PARP1和BRD4.
- 破坏DNA修复机械并诱导核-细胞质DNA泄漏,以增强STING激活.
- 评估这种策略引起的抗瘤疗效和免疫反应.
主要方法:
- 使用PROTACs来调解PARP1和BRD4的降解.
- 通过破坏DNA修复途径诱导合成致命性.
- 在临床前模型中评估了STING通路激活,免疫细胞透 (CD8+ T细胞,NK细胞) 和瘤生长.
- 评估了对肺转移的影响.
主要成果:
- 通过PROTAC介导的PARP1和BRD4的降解成功地破坏了DNA修复.
- 该策略诱导了显著的核-细胞质DNA泄漏,超过了STING激活值.
- 在多种瘤模型中表现出卓越的抗瘤疗效.
- 引起强大的CD8+T细胞和NK细胞介导的抗瘤免疫力.
- 显示抑制肺转移的进展.
结论:
- 合成致死性与PROTAC介导的PARP1和BRD4降解的整合是一个可行的策略,以增强cGAS-STING介导的先天免疫力.
- 这种方法克服了DNA修复机械所带来的局限性,从而产生强大的抗瘤反应.
- 建立了一个利用癌症免疫治疗中STING激活的新范式.
更多相关视频
07:23Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells
Published on: May 30, 2025
19:44Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen
Published on: May 30, 2012
相关概念视频
Tumor Immunotherapy
Targeted Cancer Therapies
There are several types of targeted therapies against...
Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
